Prediction of NAFLD occurrence in prediabetes patients

Vesa,Cosmin Mihai; Behl,Tapan; Nemeth,Sebestian; Bratu,Ovidiu G.; Diaconu,Camelia C.; Moleriu,Radu Dumitru; Negrut,Nicoleta; Zaha,Dana C.; Bustea,Cristiana; Radu,Florentina Ionita; Bungau,Simona

doi:10.3892/etm.2020.9320

Prediction of NAFLD occurrence in prediabetes patients

Authors:
- Cosmin Mihai Vesa
- Tapan Behl
- Sebestian Nemeth
- Ovidiu G. Bratu
- Camelia C. Diaconu
- Radu Dumitru Moleriu
- Nicoleta Negrut
- Dana C. Zaha
- Cristiana Bustea
- Florentina Ionita Radu
- Simona Bungau
View Affiliations

Affiliations: Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania, Chitkara College of Pharmacy, Chitkara University, 140401 Punjab, India, Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania, Clinical Department 3, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department 5, ‘Carol Davila’ University of Medicine and Pharmacy, 050474 Bucharest, Romania, Department of Mathematics, Faculty of Mathematics and Computer Science, West University of Timisoara, 300223 Timisoara, Romania, Department of Psycho‑Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania, Department of Gastroenterology, Emergency University Central Military Hospital, 010825 Bucharest, Romania
Published online on: October 13, 2020 https://doi.org/10.3892/etm.2020.9320
Article Number: 190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑alcoholic fatty liver disease (NAFLD) is a component of metabolic syndrome that significantly increases the cardiovascular risk of patients with glucose metabolism alterations. This study identified the prevalence of NAFLD, predictors of NAFLD and explored the link between insulin sensitivity, insulin resistance and leptinemia in 143 patients registered with prediabetes. Abdominal ultrasound was performed, and fasting insulin, postprandial insulin, leptin levels, common clinical/biochemical determinations were assessed. Certain variables that can predict NAFLD existence were determined and it was found that there is a high prevalence of NAFLD in patients with prediabetes. In univariate analysis, statistically significant associations (P<0.05) were found between waist circumference, systolic blood pressure, diastolic blood pressure, triglycerides, HDL‑cholesterol, insulin sensitivity, β‑cell function, leptin and NAFLD presence. The coefficients for the variables which obtain statistically significant association (P<0.05) are low, except for leptin which is the biochemical parameter that (in both univariate and multivariate analysis) is a strong predictor of NAFLD presence.

View Figures

View References

1	Caldwell S and Argo C: The natural history of non-alcoholic fatty liver disease. Dig Dis. 28:162–168. 2010.PubMed/NCBI View Article : Google Scholar
2	Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Bermacki D, Orsak B, Subbarayan S, Webb A, Hecht J and Cusi K: High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 100:2231–2238. 2015.PubMed/NCBI View Article : Google Scholar
3	Hazlehurst JM, Woods C, Marjot T, Cobbold JF and Tomlinson JW: Non-alcoholic fatty liver disease and diabetes. Metabolism. 65:1096–1108. 2016.PubMed/NCBI View Article : Google Scholar
4	Shibata M, Kihara Y, Taguchi M, Tashiro M and Otsuki M: Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 30:2940–2944. 2007.PubMed/NCBI View Article : Google Scholar
5	Chen Z, Yu R, Xiong Y, Du F and Zhu S: A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis. 16(203)2017.PubMed/NCBI View Article : Google Scholar
6	Veyrat-Durebex C, Poher AL, Caillon A, Somm E, Vallet P, Charnay Y and Rohner-Jeanrenaud F: Improved leptin sensitivity as a potential candidate responsible for the spontaneous food restriction of the Lou/C rat. PLoS One. 8(e73452)2013.PubMed/NCBI View Article : Google Scholar
7	Nishi T, Babazono A, Maeda T, Imatoh T and Une H: Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes. J Diabetes Investig. 6:309–316. 2014.PubMed/NCBI View Article : Google Scholar
8	Schneider AL, Lazo M, Ndumele CE, Pankow JS, Coresh J, Clark JM and Selvin E: Liver enzymes, race, gender and diabetes risk, the atherosclerosis risk in communities (ARIC) study. Diabet Med. 30:926–933. 2013.PubMed/NCBI View Article : Google Scholar
9	Remus Popa A, Fratila O, Rus M, Anca Corb Aron R, Vesa CM, Pantis C, Diaconu C, Bratu O, Bungau S and Nemeth S: Risk factors for adiposity in the urban population and influence on the prevalence of overweight and obesity. Exp Ther Med. 20:129–133. 2020.PubMed/NCBI View Article : Google Scholar
10	Vesa CM, Popa L, Popa AR, Rus M, Zaha AA, Bungau S, Tit DM, Corb Aron RA and Zaha DC: Current data regarding the relationship between type 2 diabetes mellitus and cardiovascular risk factors. Diagnostics. 10(314)2020.PubMed/NCBI View Article : Google Scholar
11	Zhou Y and Rui L: Leptin signalling and leptin resistance. Front Med. 7:207–222. 2013.PubMed/NCBI View Article : Google Scholar
12	Ernst MB, Wunderlich CM, Hess S, Paehler M, Mesaros A, Koralov SB, Kleinridders A, Husch A, Münzberg H, Hampel B, et al: Enhanced Stat3 activation in POMC neurons provokes negative feedback inhibition of leptin and insulin signaling in obesity. J Neurosci. 29:11582–11593. 2009.PubMed/NCBI View Article : Google Scholar
13	American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. Diabetes Care. 43 (Suppl 1):S14–S31. 2020.PubMed/NCBI View Article : Google Scholar
14	Abdel-Daim MM, El-Tawil OS, Bungau SG and Atanasov AG: Applications of antioxidants in metabolic disorders and degenerative diseases: Mechanistic approach. Oxid Med Cell Longev. 2019(4179676)2019.PubMed/NCBI View Article : Google Scholar
15	Pappachan JM, Babu S, Krishnan B and Ravindran NC: Non-alcoholic fatty liver disease: A clinical update. J Clin Transl Hepatol. 5:384–393. 2017.PubMed/NCBI View Article : Google Scholar
16	Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L and Wymer M: Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 64:73–84. 2016.PubMed/NCBI View Article : Google Scholar
17	Balkau B, Lange C, Vol S, Fumeron F and Bonnet F: Group Study D.E.S.I.R. Nine-year incident diabetes is predicted by fatty liver indices: The French D.E.S.I.R study. BMC Gastroenterol. 10(56)2010.PubMed/NCBI View Article : Google Scholar
18	Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A and Tiribelli C: The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 6(33)2006.PubMed/NCBI View Article : Google Scholar
19	Cansanção K, Silva Monteiro L, Carvalho Leite N, Dávalos A, Tavares do Carmo MDG and Arantes Ferreira Peres W: Advanced liver fibrosis is independently associated with palmitic acid and insulin levels in patients with non-alcoholic fatty liver disease. Nutrients. 10(1586)2018.PubMed/NCBI View Article : Google Scholar
20	Denkmayr L, Feldman A, Stechemesser L, Eder SK, Zandanell S, Schranz M, Strasser M, Huber-Schönauer U, Buch S, Hampe J, et al: Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med. 7(562)2018.PubMed/NCBI View Article : Google Scholar
21	Diaconu C, Salmen T, Gaman MA, Bratu OG, Mischianu D, Marcu RD, Suceveanu AI, Costache RS and Pantea Stoian A: SGLT2 inhibition in patients with type 2 diabetes and cardiovascular diseases: Which are the benefits? Rom J Mil Med. 122:16–21. 2019.